Current Opinion in Oncology was launched in 1989. It is one of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The field of psychiatry is divided into 15 sections that are reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce the Journal's Section Editors for this issue.
Gil Awada (1990) studied medicine at the Vrije Universiteit Brussel (Brussels, Belgium), graduating in 2015, and subsequently started his training in Internal Medicine. In June 2021, he successfully defended his PhD thesis entitled ‘Expanding the application of targeted therapies and immune checkpoint inhibitors in advanced melanoma and recurrent glioblastoma’, under the supervision of Prof. Dr. Bart Neyns. He is currently finishing his residency in Medical Oncology at the Jules Bordet Institute, Belgium.
Gil Awada performs clinical and translational research in the field of melanoma, investigating new applications of targeted agents, combination therapies and the use of novel clinical biomarkers (such as circulating tumor DNA and imaging). His work has been presented at national and international congresses and has been published in peer-reviewed journals.
Oliver Bechter earned his MD at the University of Innsbruck, Medical School in Austria in 1998. During his residency he did a postdoctoral fellowship at the Department of Cell Biology, UTSouthwestern in Dallas, TX, USA. He earned his PhD in 2005 and is a board-certified Medical Oncologist and Hematologist since 2007. Since 2012 he is working at the University Hospital in Leuven Belgium and is a professor for Oncology at the Department of Oncology from the KU Leuven.
His research focus is telomere biology in human malignancies and melanoma biology. His clinical focus is on malignant melanoma and skin cancers and he is principal investigator of several clinical trials with a focus on drug development of new immune-oncology drugs in melanoma.
Jana Jeschke studied molecular medicine at the University of Erlangen-Nuremberg, Germany, and performed her PhD research at the Johns Hopkins University in Baltimore, USA, in the groups of Prof. Nita Ahuja and Prof. Jim Herman and in collaboration with Prof. Baylin. During this time, she made several important discoveries in the field, including the identification and functional characterization of aberrantly DNA methylated genes in breast cancer and their assessment as novel biomarkers.
In 2013, Dr Jeschke moved to Belgium to start a postdoctoral training in the Laboratory of Cancer Epigenetics at Université Libre de Bruxelles (ULB) in Brussels. Under the supervision of her lead mentor Prof. Fuks and his long-time collaborator Prof. Sotiriou, a breast cancer expert from the Jules Bordet Institute in Brussels, she explored changes of various epigenetic modifications on DNA and RNA in breast and other cancers and the clinical relevance of these aberrations for cancer diagnosis and therapy. Her most notable works include the development of an epigenetic immune signature that predicts survival and response to chemotherapy in breast cancer (JCI 2017) and the discovery of m6A mRNA methylation changes in breast cancer and their impact on pathways driving cancer progression and therapy resistance (Nature Cancer 2021).
For her research, Dr Jeschke was awarded a postdoctoral fellowship from the Belgian National Fund for Scientific Research (FNRS) in 2014. In 2022, she obtained the mandate of Chercheuse Qualifiée (Associate Professor) from the FNRS to start her own research group at ULB focusing on precision cancer epigenetics.
Dr Jeschke is a member of the Belgian Association for Cancer Research (BACR), European Association for Cancer Research (EACR), American Association for Cancer Research (AACR) and Cancer Epigenetics Society (CES) and a consultant for the “Belgian Superior Health Council”. She is an associate editor for the journal of Current Opinion in Oncology and regularly reviews for other journals publishing studies related to cancer and epigenetics.